1. Balali‐Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic & clinical Pharmacology & Toxicology. 2006;99(4):273-82. 2. Somani S, Babu S. Toxicodynamics of sulfur mustard. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1989;27(9):419-35. 3. Benschop HP, van der Schans GP, Noort D, Fidder A, Mars-Groenendijk RH, de Jong LP. Verification of exposure to sulfur mustard in two casualties of the Iran-Iraq conflict. Journal of Analytical Toxicology. 1997;21(4):249-51. 4. Emad A, Rezaian GR. Characteristics of bronchoalveolar lavage fluid in patients with sulfur mustard gas–induced asthma or chronic bronchitis. The American Journal of Medicine. 1999;106(6):625-8. 5. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature. 2007;448(7152):484-7. 6. Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends in Molecular Medicine. 2016;22(3):230-41. 7. Saber H, Saburi A, Ghanei M. Clinical and paraclinical guidelines for management of sulfur mustard induced bronchiolitis obliterans; from bench to bedside. Inhalation Toxicology. 2012;24(13):900-6. 8. Razavi SM, Ghanei M, Salamati P, Safiabadi M. Long-term effects of mustard gas on respiratory system of Iranian veterans after Iraq-Iran war: a review. Chinese Journal of Traumatology. 2013;16(3):163-8. 9. Malaviya R, Sunil VR, Cervelli J, Anderson DR, Holmes WW, Conti ML, et al. Inflammatory effects of inhaled sulfur mustard in rat lung. Toxicology and Applied Pharmacology. 2010;248(2):89-99. 10. Aragizadeh H, Soroush M-R, Javadi M-A, Azizi F, Ghasemi H, Shams J, et al. Sardasht-Iran cohort study of chemical warfare victims: design and methods. Archives of Iranian Medicine. 2009;12(1):5-14. 11. Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, et al. T helper type 17‐related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clinical & Experimental Immunology. 2009;157(2):316-24. 12. Yerkovich ST, Hales BJ, Carroll ML, Burel JG, Towers MA, Smith DJ, et al. Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation. BMC Pulmonary Medicine. 2012;12(1):1.